Q1 2026 Transmedics Group Inc Earnings Call Transcript

May 5, 2026 / 08:30 PM GMT

Release Date Price: $94.93 (-2.21%)

Transcript 10-Q8-K

Key Points

Positve

TransMedics Group Inc (TMDX) reported a strong start to 2026 with a total revenue of $174 million for Q1, representing a 21% year-over-year growth.
The company is actively expanding its product offerings with the development of the OCS Kidney Platform and the introduction of the TransMedics Controlled Hypothermic Organ Preservation System (TROPS).
TransMedics Group Inc (TMDX) is making significant strides in international markets, particularly in Europe, with plans to replicate its successful U.S. logistics model.
The company maintains a strong financial position with $462 million in cash and cash equivalents, allowing for continued investment in growth initiatives.
TransMedics Group Inc (TMDX) is focused on long-term value creation, with strategic investments in technology, infrastructure, and international expansion to drive future growth.

Negative

The U.S. Transplant Modernization Act has caused some volatility and a transient negative impact on OPO performance and overall donor numbers.
Gross margin for Q1 was approximately 58%, down 331 basis points year-over-year, due to increased internal supply chain activity and investments.
The company is experiencing challenges with the enrollment timing of its enhanced and de novo clinical programs, which have not yet contributed to results.
There is ongoing pressure on operating margins due to significant investments in growth initiatives, with expectations of up to 250 basis points below last year's operating margin.
TransMedics Group Inc (TMDX) faces competitive dynamics and market confusion, particularly in relation to its clinical programs and the introduction of new technologies like CHOPS.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TMDX.OQ - Transmedics Group Inc
Q1 2026 Transmedics Group Inc Earnings Call
May 05, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the TransMedics first quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask questions during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, simply press star one again.

I'll now turn the conference over to Hannah Jeffrey, Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.